It should be said that Wang Zihao is very good at being a human being. Since he decided to give Jiang Feng a face, he simply made the face bigger. At noon the next day, not only did he arrange for Wang Zijun and Wang Zilong to welcome him at the entrance of the Great Wall Hotel, he himself also waited in the private room early and paid off the mayor Dong, Haijiang District, Haimen City as a companion. He probably had already found out that the "Guijia Hotel" where Gui Jiayao was located was within the jurisdiction of Haijiang District.

Although I don’t know what the relationship between Jiang Feng and Gui Jiayao is, I guess there must be a great relationship, otherwise Gui Jiayao would not have asked Director Zhu to come forward to "make peace". After taking care of Gui Jia Hotel, he indirectly expressed his kindness to Jiang Feng.

Jiang Feng did not take Yue Shanshan with him, but Ye Lanqiu.

Let Ye Lanqiu show off in front of Wang Zihao. If you have any problems in the future, you can go directly to him to solve them.

As for Wang Zilong's fearful look, Jiang Feng no longer cared about it at this moment.

This person is indeed not worth Jiang Feng's care about him too much. Although he is not young, he is no different from most playboys. It's not interesting to always care about such people.

Jiang Feng agreed to come to the appointment, and this matter basically ended here, so everyone was happy to drink a meal.

...

After settled the Wang family's affairs, Jiang Feng focused his main energy on negotiating the acquisition case with Haimen Pharmaceutical Group. He planned to go to the UK to meet Abramovich after solving this matter to see if it could promote cooperation between China and Russia on oil and gas.

After a period of desalination, Jiang Feng and Haimen City came up with a solution, bypassed the supervision of central ministries and commissions, first divested the research department of Haimen Pharmaceutical Group, and established the Haimen New Drug Research Institute, which was independently controlled by the Haimen Municipal Government. From then on, the research department of Haimen Pharmaceutical Group was set up to establish a separate entrance.

Later, Jiangshi Group reached a cooperation intention with Haimen. Jiangshi Group invested 200 million yuan and obtained 80% of the equity of the research institute. Since then, it has become the new boss of a pharmaceutical research institution with a number of up to 1,200 people, mainly based on doctoral and master's degrees.

Because this case did not rise to the level of directly acquiring Haimen Pharmaceutical Group, the supervision scope of central ministries and commissions was bypassed. Only after the forces that had oppose Jiang's Group's acquisition of Haimen Pharmaceutical Group came back to their senses, it was revealed that the situation was already done.

Moreover, there is no doubt that there is any violation in this matter except for some criticism in the operation method. Because the main body of Haimen Pharmaceutical Group has not been moved, Jiang's Group only acquired a small part of it, a professional institution that has been divided by the Haimen Municipal Government.

Moreover, the price of this small-scale acquisition is quite high. After all, the research institute not only has no profitability. On the contrary, it also requires investing a lot of money every year to maintain its operation. It can be said that it is a great burden for the entire Haimen Pharmaceutical Group.

Before this, many people from Haimen Pharmaceutical Group said that the company had so many researchers, but never produced any decent research results. Instead, large research expenses and personnel expenses dragged Haimen Pharmaceutical Group to a shaky and overwhelmed, so some people had long wanted to lay off the research department. The company representatives had already made this proposal, but the group had never dared to take any action, for fear of causing some big things.

After all, a few years ago, due to the laid-off of enterprises, a lot of people who affected the stability of the local area were exposed. At this time, from corporate leaders to local leaders, they were generally unwilling to touch the interests of this area.

At this time, Jiang Feng took action, and the Haimen City leaders, especially the mayor of Haimen City, Gui Chengzhong, who has close ties with the Rong family, immediately made a decision. Respect the previous opinions of Haimen Pharmaceutical Group and independent research departments. Taking the path of market-oriented operation, the government and Jiang Group jointly established a joint venture with the joint-stock research institute. The benefits produced will be divided by the two according to the equity ratio.

However, Jiang's Group also stated that as Jiang's Group continues to inject new funds into the research institute, the proportion of equity held by the Haimen Municipal Government in the research institute will be diluted accordingly.

"In other words, if the Jiang Group invested more than 2 billion yuan, the proportion of equity held by the Haimen Municipal Government in the research institute will be less than 2%?" After learning the news, Yang Shimin asked Jiang Feng, "It seems that you are determined to win this research department."

"That's very natural." Jiang Feng nodded and replied, "In fact, what I really care about is the research team of Haimen Pharmaceutical Group. After all, the strength of this team is still very strong. It's just that it is limited to the system and has not played the role it deserves. Now that it has been staked, I can use him to do a lot of things."

Jiang Feng has many good things in his hands, such as the medical secret recipes in Lingxi Ring. These things can be operated commercially to make them more conducive to promotion.

However, turning traditional Chinese medicine preparations into tablets or capsules, oral liquids that are suitable for the current market demand requires repositioning, and some pathological tests and toxicity analysis are made, or there are also various experimental requirements that need to meet the requirements of the International Organization for Standardization, and finally a result that can enable new drugs to be marketed.

All of this requires a professional research team to do, and it is not possible to do the ability of one or two people. Although Jiangshi Pharmaceutical, a subsidiary of Jiangshi Group, has a very short foundation after all, and it is too fast to expand over the years, it is difficult to draw more strength to do this.

Jiang Feng seized the time to promote new drug research and promotion, mainly because he felt the huge pressure from European and American drugs, and wanted to make the domestic drug market come to a bloody path and regain many lost traditional drug markets.

In recent years, it has been generally believed that the United States has overshadowed Europe in terms of drug research capabilities. However, according to the analysis of all data over the past 20 years, in terms of drug innovation, the United States has not surpassed Europe in the research efficiency of new drugs, and Europe's new drug research capabilities are still ahead of the United States. Compared with the new drugs previously prescribed, the clinical efficacy of most new drugs has not increased significantly.

Official and industry reports once generally believed that the United States had surpassed Europe in the prescribed new drugs. However, although the US Congress and a large number of investors are encouraging pharmaceutical companies to open and sell new drugs, these new drugs have no real value, and the efficacy of new drugs is only slightly smaller than that of old drugs.

The United States has been developing rapidly in the research of global drugs, innovators, biological products and orphan drugs, but Europe's research capabilities have hardly decreased, and Europe is still leading in opening and global high interest rates.

It is obvious that the United States has not had Europe in terms of the new compounds.

The so-called "orphan drugs" are drugs used to prevent, treat and diagnose rare diseases. Since there are few people with rare diseases, few market demand and high research costs, few pharmaceutical companies pay attention to the research of their therapeutic drugs, so these drugs are vividly called "orphan drugs".

At present, my country's research on "orphan drugs" is still in a blank state. Treatment drugs for patients with rare diseases are basically dependent on foreign imports. As a result, many patients with rare diseases can only choose expensive imported drugs or no drugs available.

The research capabilities and total research investment of drugs are often confused. A very typical publicity is that since the beginning of the two thousand years, the United States has developed itself into a major innovator in pharmaceuticals.

This statement originates from the United States investing more funds into research departments. But it is still unknown how many real new ideas are in the United States' laboratories.

Moreover, many responsible experts say that the conclusion that most new drugs are of high quality or are important to patients is also untenable.

From the perspective of patients, doctors and health policy, quality means that new drugs are clinically more effective or have fewer side effects than existing drugs. However, many current survey reports do not use data or treatment results to evaluate the quality of new drugs. Advertisements of some new drugs have obviously misled consumers and promoted the significant effect of new drugs. However, from the clinical manifestations of patients taking the drug, the efficacy of the two is almost the same.

In short, commercial success often does not equate to a significant improvement in efficacy.

At present, it is indeed necessary to encourage companies to prescribe new drugs that are better than existing drugs than existing drugs, rather than prescribe drugs that are just better than placebo. Therefore, some scholars suggest that independent clinical trials be sponsored by public institutions such as the National Institute of Health in the United States, so that they can compare the advantages and risks with existing treatment methods. Publicly sponsored trials can also reduce costs and risks for manufacturers, and improve the research and competitiveness of small factories by reducing high-cost barriers.

"Now the government has completely relaxed the approval of new drugs. There are probably no less than 20,000 new drugs released every year, but there are really no new drugs, and there are not even a hundred. The others are just old drugs that are replaced with new names after changing their packaging." When Jiang Feng mentioned this issue, he said to Yang Shimin, "For example, the drugs that often appear in TV advertisements are actually upgraded versions of very simple cold powders, or they are simply the same thing that has changed the packaging method. Not only has the effect not improved, or it has also been reduced, but the price is several times or dozens of times higher than the original product. This is very unfavorable for consumers who do not know the truth."

Jiang Feng is very clear that in response to the current problems of domestic innovative drug research companies not paying enough attention, insufficient investment, and not keeping up with basic research, it is not possible to rely on the government to change this situation. Maybe it is only possible to do some things by yourself.

To rank among the world's leading talents in the research and production of innovative drugs, we must first create a group of outstanding talents, including excellent technical talents and management talents. Therefore, what we should first solve is the problem of the basic application and incentive mechanism for scientific researchers, and explore the options and equity issues of scientists when intangible assets are invested. This mainly includes scientific researchers within scientific research institutes and enterprises.
Chapter completed!